CRITIC
img-contested
N/A
0 reviews
PUBLIC
img-contested
N/A
0 reviews
RECENT ARTICLES
gold-cheese89%
Trump’s vaccine czar says the first vaccine should be submitted for emergency authorization around Thanksgiving

Trump’s vaccine czar says the first vaccine should be submitted for emergency authorization around Thanksgiving

This interview is part of a series of conversations MarketWatch is conducting with some of the leading voices in the U.S. on COVID-19 pandemic. Moncef Slaoui, an immunologist by training and a longtime pharmaceutical executive, is running the Trump administration’s Operation Warp Speed program to spur development of vaccines on the fastest ever timetable.While none of the four vaccine candidates to enter Phase 3 trials have publicly reported data from the mid-stage studies, Slaoui is hopeful that drug makers will file for emergency authorization with the Food and Drug Administration by late...

marketwatch.com
Jaimy Lee
Oct 8
Worthy
Share
Save
Give Tip
Review
gold-cheese89%
Dr. Osterholm: Americans will be living with the coronavirus for decades

Dr. Osterholm: Americans will be living with the coronavirus for decades

This interview is the first in a series of conversations MarketWatch will conduct with some of the leading voices in the U.S. on the COVID-19 pandemicOn Jan. 20, just nine days after Chinese health authorities published the DNA sequence for a new coronavirus that had sickened dozens of people in China, Dr. Michael Osterholm, an epidemiologist at the University of Minnesota, wrote in an : “I’m certain this will cause our next pandemic.”The next day the Centers for Disease Control and Prevention confirmed the of someone infected with what became known as COVID-19. Since then, as outbreaks...

marketwatch.com
Jaimy Lee
Aug 1
Worthy
Share
Save
Give Tip
Review
gold-cheese89%
Moderna's stock falls the day after 'disappointing' patent ruling

Moderna's stock falls the day after 'disappointing' patent ruling

Shares of Moderna Inc.were down 4.7% in premarket trading on Friday, the day after the U.S. Patent and Trademark Office in favor of Arbutus Biopharma Corp.in a patent dispute between the companies. Shares of Arbutus rallied 15.9% on Friday before the market opened. The decision may mean that Arbutus will attempt to make a royalty claim to products developed by Moderna's lipid nanoparticle delivery technology, which is currently being used to develop a COVID-19 vaccine. SVB Leerink's Mani Foroohar said the ruling is a "disappointing turn" for Moderna, and "any meaningful royalty burden could...

marketwatch.com
Jaimy Lee
Jul 24
Worthy
Share
Save
Give Tip
Review
gold-cheese89%
Gilead’s coronavirus drug will cost $2,340 — which sounds expensive, but here’s why it’s not

Gilead’s coronavirus drug will cost $2,340 — which sounds expensive, but here’s why it’s not

Gilead Sciences Inc.’s COVID-19 drug remdesivir will cost much less than Wall Street analysts had predicted in a move that likely points to a more measured, responsible approach to the pricing of treatments and vaccines during the pandemic.Shares of Gileadgained 0.9% in trading on Monday following the made before the market opened. U.S. health officials separately said Monday morning that the government of remdesivir for Americans through September, to be purchased by hospitals.The cost of remdesivir for a 5-day course of treatment is $2,340 in all developed countries, a price tag that is...

marketwatch.com
Jaimy Lee
Jun 29
Worthy
Share
Save
Give Tip
Review
gold-cheese89%
Gilead drug produced ‘rapid’ recovery in coronavirus patients, report says

Gilead drug produced ‘rapid’ recovery in coronavirus patients, report says

University of Chicago Medicine researchers said they saw “rapid recoveries” in 125 COVID-19 patients taking Gilead Sciences Inc.’s experimental drug remdesivir as part of a clinical trial, according to a Thursday afternoon report.Shares of Gilead Sciences Inc.jumped 12.7% in after-hours trading on Thursday following the publication of .There are no proven treatments or vaccines for the novel coronavirus which has sickened more than two million people world-wide and killed nearly 150,000 people, but remdesivir is considered a front-runner in the race to develop a treatment for COVID-19...

marketwatch.com
Jaimy Lee
Apr 16
Worthy
Share
Save
Give Tip
Review
OUTLETS
marketwatch.com

marketwatch.com

CRITIC
img-contested
N/A
PUBLIC
img-trusted
89%